general epilepsy population. 10, 12 Enzymeinducing AEDs decrease the efficacy of certain chemotherapeutic agents and have been known to reduce corticosteroid efficacy as well. 13 There are no evidencebased treatment guidelines, and optimal antiepileptic therapy in patients with brain tu mors remains elusive. Firstline treatment using AEDs fails to control seizures in about 60% of patients, and among those who receive secondline monotherapy or polyphar macy, the treatment fails in approximately 60%. 12 Recently, however, second and thirdgeneration AEDs have been in troduced and approved for the treatment of seizures, and the rate of response in brain tumor-induced seizures often exceeds 50%. 9 Lacosamide (Vimpat, UCB Pharma) is a thirdgen eration AED that has a novel mechanism of action of selectively enhancing slow inactivation of voltagegated sodium channels. It was approved by the FDA in October 2008 as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy. 1, 2, 4 Lacosamide has many favorable properties for use in patients with brain tumors. It has a favorable pharmacokinetic profile that includes low protein binding, a 13hour halflife that permits twice daily administration, rapid and complete oral absorption not affected by food intake, no induction or inhibition of hepatic enzymes, and a very low poten tial for drug interactions. 1 It is available in the intrave nous form with easy 1:1 dose conversion to/from the oral preparation. It has also been reported to be well tolerated, and most adverse events related to the CNS and gastro intestinal events were mild to moderate. 4 In addition, it has been noted that lacosamide is less likely than other AEDs to cause other concerning adverse events such as drugrelated rash, weight gain or loss, sedation, or mood dysfunction. 2 To the best of our knowledge, no published stud ies have been focused on the tolerability and activity of lacosamide in controlling seizures in patients with brain tumors. Therefore, in this retrospective descriptive analy sis, we aimed to determine the tolerability and activity of lacosamide in patients with brain tumors.
Methods
We conducted an institutional review board-ap proved retrospective chart review of all brain tumor pa tients who had received lacosamide for seizure manage ment at 5 academic medical centers with tertiary brain tumor programs in the US (Brigham and Women's Hos pital, Boston; CedarsSinai Medical Center, Los Angeles; University of California, Irvine; University of California, San Diego; and University of Washington, Seattle). Cri teria for study eligibility included the diagnosis of a pri mary brain tumor and placement on lacosamide. Indica tions for initiating lacosamide therapy included seizure activity that did not respond to prior AEDs, unacceptable adverse effects from previous therapy, or prophylaxis. We collected data on patient demographics, tumor his tology, and tumor treatment (Table 1) . Seizure type and frequency and use of AEDs were extracted from patient histories and clinic progress notes (Table 2 ). Seizure fre quency data were collected for the time prior to the start of lacosamide therapy. Because of the marked variability in seizure frequency over time, the lack of appropriate objective criteria for evaluating the response to treatment, and the multiple indications for initiating lacosamide, therapeutic activity was defined as any self-reported de crease in seizure frequency.
Results

Patient Characteristics
The charts for 70 patients with a median age of 51 years and a median follow-up of approximately 6.2 months were reviewed across the 5 sites (Table 1) . Glioblastoma accounted for the highest percentage of cases (40%), fol lowed by Grade II gliomas (36%). More than 81% of the cohort had received some form of radiotherapy, and ap proximately 84% of patients had received some form of chemotherapy. Fifty-five (78%) of the 70 patients suffered from partial seizures, while only 12 (17%) reported hav ing generalized seizures. With the exception of 12 patients (17%), most were taking other AEDs concurrently with 
lacosamide (Table 3). A majority of the patients (35 [50%])
were on levetiracetam (Keppra, UCB Pharma) in addition to lacosamide. Eleven patients were taking NEIAEDs con currently with lacosamide, whereas 12 patients were tak ing EIAEDs concurrently with lacosamide.
Lacosamide Tolerability
Most of the patients (74%) were started on lacos amide because of recurrent seizures (Table 2) . Thirty-five patients (50%) were maintained on a total dose of 200 mg daily. Most patients (54 [77%]) did not report any toxicities. Four patients reported more than one toxicity. The most common toxicity was fatigue (4 cases [6%]), followed by dizziness, nausea, confusion, and weakness (2 cases each). Patients experienced toxicities at several different doses. Of those who did experience toxicities (16 patients), 6 (37.5%) were taking lacosamide as a single agent and 6 (37.5%) were taking lacosamide concurrently with levetiracetam (Table 3) .
Lacosamide Activity
Forty-six patients (66%) reported a decrease in sei zures, and 38 of these patients (83%) reported a greater than 50% decrease in seizure frequency. Twentyone pa tients (30%) reported stable seizures (Table 2) . Fiftyfour patients (77%) did not require the addition of other AEDs following lacosamide therapy, whereas 16 (23%) required the addition of another AED to manage their seizures. Of those who started lacosamide because they were ex periencing seizures (52 patients), 73% had a decrease in seizure frequency. Lacosamide was added on to EIAEDs and NEIAEDs, and the tolerability was similar. Lacos amide showed activity regardless of the prior AED class (Table 3 ). In particular, lacosamide was active in patients on levetiracetam, with 71% reporting a decrease in seizure frequency on combination therapy. Of those who were on lacosamide monotherapy, 33% reported a decrease in sei zure frequency. Of those who were on NEIAEDs concur rently with lacosamide, 64% reported a decrease in seizure frequency. Of those who were on EIAEDs concurrently with lacosamide, 83% reported a decrease in seizure fre quency. Further subset analysis of other clinical factors was not possible given the limited sample size.
Discussion
It has been suggested that the ideal AED for patients with brain tumors should be prescribed after the first sei zure with the goal of complete seizure control while pre venting significant adverse effects and pharmacokinetic interactions. 8 Current prescribing practices are guided mainly by the tolerability and toxicity profile of each AED. Between 1989 and 2009, 14 second and thirdgen eration AEDs were approved for clinical use in both the US and Europe. Of these new AEDs, 5 were not associ ated with clinically significant pharmacokinetic interac tions: gabapentin, lacosamide, levetiracetam, pregabalin, and vigabatrin. 5 Gabapentin has been evaluated in pa tients with brain tumors and along with levetiracetam has been recommended as an addon treatment for the control of seizures in patients with brain tumors. 12 Levetiracetam and pregabalin have also been investigated as monother apy in brain tumor-related seizures. 8 The clinical use of vigabatrin, licensed in 1989, has decreased because of its serious potential adverse effect of visual field defects.
5
Brain tumor patients with a history of seizures will require longterm treatment with AEDs taken concur rently with other drugs for the management of the tumor and treatmentrelated adverse effects. However, the risk of drug interactions between anticancer drugs and AEDs is high, particularly when traditional EIAEDs are used. 14 Of the newer AEDs, lacosamide has not been evaluated in a population of patients with brain tumors. Based on the pharmacokinetics and reported interactions with AEDs and other drugs, 14 the use of lacosamide in patients with brain tumors appears to be desirable.
In our population, lacosamide was effective in reduc ing seizure frequency in 66% of patients. The activity was even greater (73%) in the subset of patients who were placed on lacosamide because of seizures unresponsive to previous therapy. These results compare favorably with those for levetiracetam, for which a significant decrease in seizures has been reported in 47%-82% of patients with epilepsy. 6, 7 This finding indicates that lacosamide can be considered as an addon therapy in patients with brain tumors to reduce seizure frequency. Lacosamide's novel mechanism of action will allow for concurrent use with other AEDs, as documented by its activity across many different types of AEDs in our population.
Lacosamide was also well tolerated in most patients, with 77% reporting no toxicities. The most common ad verse events of lacosamide reported in clinical trials are dizziness, headache, fatigue, nausea, and diplopia and were dose related.
1,2,4 These adverse effects were also ob served in our sample, but with a lower frequency than reported in the clinical trials (Table 2) . Furthermore, neurocognitive deficits associated with the use of AEDs, particularly among patients with brain tumors, 9 were not observed in our sample. And there were no reports of cardiac adverse effects or liver function test abnormali ties. In addition, most patients (77%) who were started on lacosamide did not have another addon agent at a median followup of 6.2 months.
Conclusions
We acknowledge the limitations inherent to retrospec tive medical record reviews, which can only be addressed by conducting a larger prospective study evaluating the ef ficacy and tolerability of lacosamide in patients with brain tumors. In the meantime, we cautiously conclude that our retrospective analysis has demonstrated that lacosamide was both well tolerated and showed activity as an addon AED in patients with brain tumors. Furthermore, patients on lacosamide monotherapy (n = 12) also benefitted. The unique safety and tolerability benefits demonstrated, as compared with those for traditional AEDs, make the op tion of using lacosamide as an addon treatment viable for patients with brain tumors. While this paper was under review, a report on only 14 patients confirmed our find ings on the activity of lacosamide in brain tumor-related epilepsy. 6 
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